WALTHAM, Mass., Aug. 22, 2022(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that the
WALTHAM, Mass., Aug. 22, 2022 Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today. | August 22, 2022
A digital medicine system appeared to improve clinical schizophrenia symptoms beyond the effects of oral pharmacotherapy alone, according to study results presented at Psych Congress. “This work uses data from a digital medicine system that consists of tablets of the atypical antipsychotic aripiprazole, embedded with an ingestible event marker,” J. Corey Fowler, PhD, director of